Paired Ends

Premium

Oxford Nanopore has appointed Peter Allen to non-executive director of the board. He currently serves as non-executive chairman on the boards of ProStrakan Group, Chroma Therapeutics, and Proximagen Neuroscience. Previously, he served as chief financial officer for Abacus Group and Celltech Group. He was also the deputy CEO of Celltech until the company was sold in 2004. Allen succeeds Riccardo Pigliucci, who is retiring.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.